Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
- 16 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (9), 4517-4527
- https://doi.org/10.1021/acs.jmedchem.9b01392
Abstract
JAK1 together with JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways are associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK and AKT, and is associated with resistance or poorer response to agents targeting these pathways. Amongst the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling, therefore selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from a promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with approved EGFR inhibitor, osimertinib, in a preclinical non-small cell lung cancer (NSCLC) xenograft NCI-H1975 model.Keywords
This publication has 41 references indexed in Scilit:
- The regulation of JAKs in cytokine signaling and its breakdown in diseaseCytokine, 2019
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to MethotrexateArthritis & Rheumatology, 2017
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid ArthritisArthritis & Rheumatology, 2017
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1Expert Opinion on Therapeutic Patents, 2016
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasisBritish Journal of Dermatology, 2016
- Baricitinib in Patients with Refractory Rheumatoid ArthritisThe New England Journal of Medicine, 2016
- Biology and significance of the JAK/STAT signalling pathwaysGrowth Factors, 2012
- BCR-ABL1—Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and TreatmentClinical Lymphoma Myeloma and Leukemia, 2011
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant RejectionJournal of Medicinal Chemistry, 2010
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisThe New England Journal of Medicine, 2010